Streetbeat News

Regulatory

IBRX

ImmunityBio, Inc. (IBRX) presented promising Phase 2 data at the World Conference on Lung Cancer, showing prolonged survival in NSCLC patients using ANKTIVA with checkpoint inhibitors. The data supports Phase 3 trials and potential global launch.

Portfolio Pulse from Benzinga Newsdesk

September 09, 2024 | 12:36 pm

SOAR

Volato has announced that the New York Stock Exchange (NYSE) has accepted its compliance plan. This development is crucial for Volato as it works to meet the NYSE's listing standards.

Portfolio Pulse from Benzinga Newsdesk

September 09, 2024 | 12:31 pm

KTTA

Pasithea Therapeutics has completed long-term chronic toxicity studies for its lead candidate PAS-004, a MEK inhibitor, in rats and dogs. The studies confirm a consistent safety profile, supporting ongoing Phase 1 trials in advanced cancer patients.

Portfolio Pulse from Benzinga Newsdesk

September 09, 2024 | 12:20 pm

MBRX

Moleculin Biotech has announced the enrollment of patients in a Phase 2 study of WP1066 combined with radiation for glioblastoma treatment. The study is conducted at Northwestern University and funded by NIH and BrainUp.

Portfolio Pulse from Benzinga Newsdesk

September 09, 2024 | 12:19 pm

BIOR

Biora Therapeutics, Inc. has achieved ISO 13485:2016 certification, highlighting its commitment to global regulatory and quality standards.

Portfolio Pulse from Benzinga Newsdesk

September 09, 2024 | 12:13 pm

HSAI

Hesai Technology has become the first company in the global lidar industry to receive the ISO 21448 Safety of the Intended Functionality certification. This achievement underscores Hesai's commitment to safety and innovation in lidar technology.

Portfolio Pulse from Benzinga Newsdesk

September 09, 2024 | 12:10 pm

TARA

Protara Therapeutics announced results from the THRIVE-1 study, highlighting a high prevalence of choline deficiency and liver injury in patients dependent on parenteral support. The company plans to start a pivotal trial for IV Choline Chloride in Q1 2025.

Portfolio Pulse from Benzinga Newsdesk

September 09, 2024 | 12:09 pm

TARA

Protara Therapeutics has completed the first cohort of its Phase 2 STARBORN-1 trial for TARA-002, targeting pediatric lymphatic malformations. Enrollment for additional cohorts is ongoing, with initial results anticipated in the first half of 2025.

Portfolio Pulse from Benzinga Newsdesk

September 09, 2024 | 12:08 pm

GERN

MCK

Biologics by McKesson has been selected by Geron Corporation as a limited specialty pharmacy provider for RYTELOTM, a newly FDA-approved treatment for certain myelodysplastic syndromes. RYTELOTM is a first-in-class telomerase inhibitor targeting patients with transfusion-dependent anemia.

Portfolio Pulse from Benzinga Newsdesk

September 09, 2024 | 12:06 pm

SINT

SINTX Technologies has received a Notice of Allowance for a U.S. patent on the surface functionalization of zirconia-toughened alumina with silicon nitride ceramic. This development could enhance their product offerings and market position.

Portfolio Pulse from Benzinga Newsdesk

September 09, 2024 | 12:06 pm